News Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-10 pm EDT			5-day change	1st Jan Change
748.87 ^USD	-2.47%		-1.70%	-2.98%

Apr. 08	Bernstein Adjusts Regeneron Pharmaceuticals Price Target to $921 From $925, Maintains Outperform Rating	MT
Apr. 08	Regeneron Expects $0.81 per Share Net Income Impact From $102 Million R&D Charges for Q1	MT

All News

Apr. 08	Bernstein Adjusts Regeneron Pharmaceuticals Price Target to $921 From $925, Maintains Outperform Rating	MT
Apr. 08	Regeneron Expects $0.81 per Share Net Income Impact From $102 Million R&D Charges for Q1	MT
Apr. 07	RBC Adjusts Price Target on Regeneron Pharmaceuticals to $779 From $765, Maintains Sector Perform Rating	MT
Apr. 06	Raymond James Adjusts Price Target on Regeneron Pharmaceuticals to $910 From $870, Maintains Outperform Rating	MT
Apr. 02	TrinetX collaborates with Regeneron to access de-identified electronic health records of 300 million patients to drive research and product development in life sciences and digital health solutions	RE
Apr. 02	Regeneron Taps TriNetX for Health Records of 300 Million Patients to Boost Research	MT
Apr. 02	TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions	PR
Apr. 02	TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions	AQ
Apr. 02	Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions	GL
Apr. 02	Regeneron says it expects to avoid new US pharma tariffs	RE
Apr. 02	Regeneron Says FDA Approves Expansion of Eylea HD Dosing Intervals	MT
Apr. 02	Regeneron Gets FDA OK for Extended Eylea HD Dosing	DJ
Apr. 02	Eylea HD approved by FDA as first and only injectable anti-VEGF with dosing intervals up to 5 months	RE
Apr. 02	EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)	GL
Apr. 02	Regeneron Pharmaceuticals Announces Eylea Hd Approval for Extended Dosing Intervals in Wet Age-Related Macular Degeneration and Diabetic Macular Edema	CI
Apr. 02	Regeneron Pharmaceuticals, Inc. Announces That the U.S. Food and Drug Administration Approves the Extension of Dosing Intervals for Eylea Hd	CI
Apr. 01	JPMorgan American Investment Trust lags benchmark but lifts payout	AN
Mar. 29	China's Hansoh Pharmaceutical Group beats net profit expectations in 2025	RE
Mar. 27	AstraZeneca drug reduces flare-ups of chronic lung disease in late-stage trials	RE
Mar. 25	Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026	GL
Mar. 24	Sanofi and Regeneron Receive Approval for Dupixent in Japan as First Targeted Medicine to Treat Adults with Bullous Pemphigoid	CI
Mar. 24	Regeneron Pharmaceuticals, Inc. and Sanofi Approve Dupixent for Treatment of Adults with Bullous Pemphigoid in Japan	CI
Mar. 24	Japan Clears Sanofi, Regeneron's Dupixent as First Targeted Therapy for Rare Skin Disease	MT
Mar. 24	Regeneron, Sanofi's Dupixent Approved in Japan as Bullous Pemphigoid Treatment	MT
Mar. 24	Sanofi, Regeneron Win Japanese Regulatory Nod for Skin Disease Treatment in Adults	MT